<div class='circular--portrait' style='background:#1A69FC;color: #ffffff;font-size:4em;'>RB</div>
RGRX -- USA Stock  

USD 0.19  0.03  13.64%

REGENERX BIOPHARMACEUTICA is scheduled to announce its earnings tomorrow. While some baby boomers are getting worried about healthcare space, it is reasonable to break down REGENERX BIOPHARMACEUTICALS as an investment alternative. We will evaluate why recent REGENERX BIOPHARMACEUTICA price moves suggest a bounce in May.
Published six days ago
View all stories for REGENERX BIOPHARMACEUTICA | View All Stories
Does REGENERX BIOPHARMACEUTICA (OTC:RGRX) has enough cash to last in May?
REGENERX BIOPHARMACEUTICA currently holds 1.03 M in liabilities. This firm has a current ratio of 1.18, suggesting that it may have difficulties to pay its financial obligations when due.
The company holds a Beta of -1.9713, which implies a somewhat significant risk relative to the market. Let's try to break down what REGENERX's beta means in this case. As returns on the market increase, returns on owning REGENERX BIOPHARMACEUTICA are expected to decrease by larger amounts. On the other hand, during market turmoil, REGENERX BIOPHARMACEUTICA is expected to outperform it. Even though it is essential to pay attention to REGENERX BIOPHARMACEUTICA current trending patterns, it is always good to be careful when utilizing equity existing price patterns. Our way of forecasting any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. REGENERX BIOPHARMACEUTICA exposes twenty-one different technical indicators, which can help you to evaluate its performance. REGENERX BIOPHARMACEUTICA has an expected return of -0.0908%. Please be advised to check REGENERX BIOPHARMACEUTICA downside deviation, treynor ratio, as well as the relationship between the Treynor Ratio and expected short fall to decide if REGENERX BIOPHARMACEUTICA stock performance from the past will be repeated in the future.
REGENERX BIOPHARMACEUTICA financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of REGENERX BIOPHARMACEUTICA, including all of REGENERX BIOPHARMACEUTICA's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of REGENERX BIOPHARMACEUTICA assets, the company is considered highly leveraged. Understanding the composition and structure of overall REGENERX BIOPHARMACEUTICA debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it.
Please read more on our technical analysis page.

Watch out for price decline

Please consider monitoring REGENERX BIOPHARMACEUTICA on a daily basis if you are holding a position in it. REGENERX BIOPHARMACEUTICA is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the otc stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as REGENERX BIOPHARMACEUTICA stock to be traded above the $1 level to remain listed. If REGENERX BIOPHARMACEUTICA stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is REGENERX BIOPHARMACEUTICA's Liquidity

REGENERX BIOPHARMACEUTICA financial leverage refers to using borrowed capital as a funding source to finance REGENERX BIOPHARMACEUTICALS ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. REGENERX BIOPHARMACEUTICA financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between REGENERX BIOPHARMACEUTICA's total debt and its cash.

How REGENERX utilizes its cash?

To perform a cash flow analysis of REGENERX BIOPHARMACEUTICA, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash REGENERX BIOPHARMACEUTICA is receiving and how much cash it distributes out in a given period. The REGENERX BIOPHARMACEUTICA cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Bona fide gift to Allan Goldstein of 200000 shares of REGENERX BIOPHARMACEUTICA subject to Section 16

Legal trades by REGENERX BIOPHARMACEUTICA insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
REGENERX insider trading alert for gift of common stock by Allan Goldstein, the corporate stakeholder, on 8th of February 2021. This event was filed by Regenerx Biopharmaceutica with SEC on 2021-02-08. Annual statement of changes in beneficial ownership - SEC Form 5. Allan Goldstein currently serves as founder, chairman, chief scientific advisor and chairman of medical and scientific advisory board of REGENERX BIOPHARMACEUTICA [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper Perspective

The small slide in market price for the last few months created some momentum for investors as it was traded today as low as 0.23 and as high as 0.26 per share. The company executives did not add much value to REGENERX BIOPHARMACEUTICA investors in March. However, diversifying your holdings with REGENERX BIOPHARMACEUTICA or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 30 days investing horizon is currently 11.66. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the REGENERX BIOPHARMACEUTICA partners.


The kurtosis is down to 13.56 as of today. REGENERX BIOPHARMACEUTICALS is displaying above-average volatility over the selected time horizon. Investors should scrutinize REGENERX BIOPHARMACEUTICALS independently to ensure intended market timing strategies are aligned with expectations about REGENERX BIOPHARMACEUTICA volatility. REGENERX BIOPHARMACEUTICALS is a potential penny stock. Although REGENERX BIOPHARMACEUTICA may be in fact a good instrument to invest, many penny otc stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in REGENERX BIOPHARMACEUTICALS. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on REGENERX instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

While other entities in the biotechnology industry are either recovering or due for a correction, REGENERX BIOPHARMACEUTICA may not be performing as strong as the other in terms of long-term growth potentials. To summarize, as of the 4th of April 2021, we see that REGENERX BIOPHARMACEUTICA very regressive towards the market. The company is undervalued with average probability of financial unrest within the next 24 months. However, our up-to-date 30 days Buy-Hold-Sell recommendation on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of REGENERX BIOPHARMACEUTICALS. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to